New York University School of Medicine
New York, 10016, United States
Location status: Recruiting
Location contact
Aravinda Chakravarti, PhD
PRINCIPAL_INVESTIGATOR
Monica Erazo, MS
CONTACT
NCT Number: NCT00478712
Hirschsprung disease is a genetic condition caused by lack of nerve cells in varying lengths of the intestines. This study will investigate the complex genetic basis of the disease, which involves multiple interacting genetic factors.
Interested in participating?
Request Info1 week–100 year
All sexes
Observational
New York, 10016, United States
Location status: Recruiting
Aravinda Chakravarti, PhD
PRINCIPAL_INVESTIGATOR
Monica Erazo, MS
CONTACT
Hirschsprung disease (HSCR) is a birth defect resulting from the absence of nerve (ganglion) cells in the gastrointestinal tract. Hirschsprung disease has a population incidence of 1/5000 live births and most often occurs as an isolated condition. However, approximately 30% of HSCR cases are associated with other birth defects such as Down syndrome, deafness, hypopigmentation, and congenital central hypoventilation syndrome. Hirschsprung disease is a genetic condition with autosomal dominant, autosomal recessive, and multigenic patterns of inheritance described.
Dr. Aravinda Chakravarti's laboratory has been investigating the genetics of Hirschsprung disease (HSCR) for more than twenty five years. The goal of this research study is to identify genes harboring causative HSCR mutations and to better understand the complex inheritance of HSCR in families by whole genome mapping and sequencing studies. Specifically, the study aims to determine the frequency with which mutations in any human gene lead to familial and isolated forms of HSCR. Further, the study will collect clinical information and investigate possible genotype - phenotype correlations.
Molecular analysis using markers and sequencing, and statistical analysis of these data will be used to identify regions of human chromosomes where putative HSCR disease genes may be located. In addition, the DNA sequence of known and/or suspected HSCR genes will be assessed in individual patients and their family members, in search of causative HSCR susceptibility variants and variants that may affect presentation of the disease and treatment outcomes. Phenotypic information will include pathology, surgical, and other clinical outcomes related to Hirschsprung disease. This study will hopefully lead to a better understanding of the genetics of HSCR and, further down the road, improved diagnosis, treatment, and genetic counseling.
This study asks volunteers to:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
Time frame: DNA is isolated up to 1 year after enrollment
Genome-wide assays of common genetic variation will be assessed using single nucleotide polymorphism (SNP) arrays
Time frame: DNA is isolated up to 1 year after enrollment
Copy number variation will be detected using next generation sequencing data and high resolution microarrays that allow for detection of copy number variants across the genome
Time frame: DNA is isolated up to 1 year after enrollment
Exome sequencing will be used to detect rare variation across all genes in the genome
Time frame: Baseline pathology data is obtained up to 1 year after enrollment
Pathology records and surgical records will be used to determine transition zone
Time frame: Baseline clinical data is obtained up to 1 year after enrollment
Time frame: Baseline clinical data is obtained up to 1 year after enrollment
Time frame: Baseline clinical data is obtained up to 1 year after enrollment
Time frame: Baseline clinical data is obtained up to 1 year after enrollment
Time frame: Baseline clinical data is obtained up to 1 year after enrollment and follow up data is obtained up to 100 years after enrollment
Assessment of complications that lead to eventual repeat pull-through surgery
Time frame: Baseline clinical data is obtained up to 1 year after enrollment and follow up data is obtained up to 100 years after enrollment
Time frame: Baseline clinical data is obtained up to 1 year after enrollment and follow up data is obtained up to 100 years after enrollment
Contact information is provided by the study sponsor or research team.
NYU Langone Health
Other
Genetic Analysis of Hirschsprung Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06072976
Colonic Diseases, Congenital Abnormalities
Seattle, Washington, United States
View Trial DetailsNCT07519915
Colonic Diseases, Congenital Abnormalities
Erlangen, Germany
View Trial DetailsNCT06573723
Abnormalities, Multiple, Adrenal Gland Diseases
Buenos Aires, Argentina
View Trial DetailsNCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial Details